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ARTICLE OPEN
Treatment of asthma exacerbations with the human-powered
nebuliser: a randomised parallel-group clinical trial
Christopher J Hallberg1,2, M Therese Lysaught3, René Antonio Najarro4,5, Fausto Cea Gil4,5, Clara Villatoro6,
Ana Celia Diaz de Uriarte4 and Lars E Olson1
BACKGROUND: Nebulisers aid the treatment of respiratory diseases, including asthma, but they require electricity and are often
cost-prohibitive for low- and middle-income countries.
AIMS: The aim of this study was to compare a low-cost, human-powered nebuliser compressor with an electric nebuliser
compressor for the treatment of mild to moderate asthma exacerbations in adults and children.
METHODS: This was a non-blinded, parallel-group, equivalence study, with 110 subjects between 6 and 65 years of age, conducted
in the emergency department of a district hospital in Ilopango, El Salvador. Participants were assigned by random allocation to
receive a 2.5-mg dose of salbutamol from the experimental human-powered nebuliser or the electric nebuliser control. All assigned
participants completed treatment and were included in analysis. The study was not blinded as this was clinically unfeasible;
however, data analysis was blinded.
RESULTS: The mean improvement in peak ﬂow of the experimental and control groups was 37.5 (95% conﬁdence interval (CI)
26.7–48.2) l/min and 38.7 (95% CI, 26.1–51.3) l/min, respectively, with a mean difference of 1.3 (95% CI, − 15.1 to 17.7) l/min. The
mean improvement in percent-expected peak ﬂow for the experimental and control groups was 12.3% (95% CI, 9.1–15.5%) and
13.8% (95% CI, 9.8–17.9%), respectively, with a mean difference of 1.5% (95% CI, − 3.6 to 6.6%).
CONCLUSIONS: The human-powered nebuliser compressor is equivalent to a standard nebuliser compressor for the treatment of
mild-to-moderate asthma. (Funded by the Opus Dean’s Fund, Marquette University College of Engineering; ClinicalTrials.gov
NCT01795742.)
npj Primary Care Respiratory Medicine (2014) 24, 14016; doi:10.1038/npjpcrm.2014.16; published online 26 June 2014
INTRODUCTION
Approximately 300 million people worldwide suffer from asthma,
and the incidence is growing.1 Annually, asthma is responsible for
15 million disability-adjusted life years lost2 and 180,000 deaths,
most of which are preventable.3 Asthma in Latin America is a
growing public health problem.4,5 In one study, asthma control in
Latin America fell far short of goals set by international guidelines,
with only 2.4% of patients surveyed meeting all criteria.6 The
direct cost of treatment of uncontrolled asthma in Latin America is
substantial,7 much of which comes from the unscheduled use of
health care resources.8
The Global Initiative for Asthma calls for the use of rapid-acting
inhaled β-agonists for treating mild-to-moderate asthma
exacerbations.9 Salbutamol, the most common of these medica-
tions, is typically administered by metered dose inhaler or
nebulisation. Global Initiative for Asthma guidelines state that
the use of a metered dose inhaler with a spacer is at least
equivalent to treatment with a nebuliser, provided that the patient
uses the metered dose inhaler properly. Inhalers are highly
portable, do not require electricity and have a shorter treatment
duration than nebulisers. However, difﬁculty with inhaler techni-
que has been well documented in high-income countries, even
among individuals with advanced medical training, an issue not
present with nebulisers where patients simply breathe
continuously.10,11 In low- and middle-income countries, these
difﬁculties could be further exacerbated by the dearth of trained
health-care workers.
Nonetheless, nebulisers have a number of advantages. In
addition to being easy to use, they are a general-purpose medical
device capable of delivering a wide range of medications and
vaccines, and for generating sputum samples for tuberculosis
diagnosis. Jet nebulisers do require electricity or batteries in the
case of hand-held types. However, given the versatility of the
nebuliser, particularly in resource-limited countries, inhalers and
nebulisers should be viewed as complementary, not competing,
technologies.
The human-powered nebuliser (HPN) is a general-purpose
nebuliser compressor (Figure 1). It does not require electricity.
Airﬂow is generated by hand cranking by a trained operator while
the patient receives treatment. It was designed to be more
durable and affordable than the portable ultrasonic or vibrating
mesh nebulisers that carry high maintenance costs, have more
complicated cleaning procedures and overheat if they are
operated continuously. Laboratory experiments conducted by
some of the authors of this study have conﬁrmed that the ﬂow
rate, pressure and droplet size generated by the HPN are
consistent with commercially available nebulisers (currently under
review). One study has demonstrated the HPN’s effectiveness in
generating sputum samples for tuberculosis diagnosis for a
mobile test unit in South Africa.12
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This paper reports the outcome of a clinical trial comparing the
treatment of patients with mild-to-moderate asthma with
salbutamol using the HPN and a standard electric jet nebuliser
compressor (EN) at a hospital in El Salvador.
MATERIALS AND METHODS
Setting
The study was conducted in the respiratory therapy area in the emergency
department of a district hospital, Hospital Nacional San Bartolo, in
Ilopango, El Salvador, during August and September 2012. All patients
presenting to the respiratory area with an asthma exacerbation and a
physician’s order for nebulised salbutamol were screened by the study
physician for eligibility.
Study procedure
The objective of the study was to compare the effectiveness of the HPN
with an EN in the delivery of a single dose of salbutamol, for the treatment
of mild-to-moderate asthma exacerbations in patients between 6 and
65 years of age, inclusive. Clinical symptoms for inclusion were based on
Global Initiative for Asthma and Salvadoran Ministry of Health guidelines
for mild and moderate exacerbation severity classiﬁcation: (1) respiratory
rate between 30 and 60 breaths per minute; (2) pulse rate between 60 and
120 beats per minute; (3) peak expiratory ﬂow (PEF) o90% expected (best
of three attempts); and (4) oxygen saturation levels 490%.
Oxygen saturation levels were measured by a pulse oximeter (CMS50F,
Contec Medical System, Shanghai, China) and PEF was measured using a
peak ﬂow meter (ASSESS Peak Flow Meter, Respironics, Murrysville, PA,
USA). Subjects presenting with any complicating respiratory condition and
those receiving any other medication or treatment, including other asthma
medications, were excluded from the study. Pregnant women and women
who thought they may be pregnant were also excluded. All participants
had previously been diagnosed with asthma and regularly received
nebulised salbutamol for asthma exacerbations before the study. Informed
consent was obtained from adult participants and from the parent of each
assenting child subject.
This was a parallel-group trial, where each participant was randomly
assigned to receive treatment with the experimental HPN compressor
(Marquette University, Milwaukee, WI, USA) or the control EN compressor
(DeVilbiss Pulmo-Aide 5650D, Somerset, PA, USA). Device assignment was
determined by removal of a coloured tile from an opaque bag containing
55 tiles of one colour and 55 tiles of another, representing a total of 110
subjects (Figure 2). The study assistant selected the tiles and assigned each
participant to the indicated group. Identical nebulisers and masks (Hudson
RCI Micro Mist, Teleﬂex, Research Triangle Park, NC, USA) were used with
both nebuliser compressors. This trial was not blinded to the participant
and study care providers, as concealing the type of nebuliser compressor
used was unfeasible in the clinical environment. Researchers performing
data analysis were blinded to group assignment until after data analyses
were performed. Each participant received a single salbutamol dose,
2.5 mg (0.5 ml of 0.5% salbutamol sulphate) in 2.5 ml of 0.9% saline in
accordance with Global Initiative for Asthma and Salvadoran Ministry of
Health guidelines. Both nebuliser compressors were run until completion,
~ 20min. The HPN was operated by a study assistant, at a speed of
~ 60 revolutions per minute. The operation of the HPN does not require
precise speed; an internal ﬂow regulator ensures that the HPN produces
either the prescribed airﬂow or none at all.
Before inclusion in the study, PEF, heart rate, respiration rate, oxygen
saturation, blood pressure, temperature, height and weight of each subject
was collected. During treatment, oxygen saturation and heart rate were
recorded every 5min, and the patient was under constant supervision by
the study physician. On completion of the treatment, ﬁnal oxygen
saturation and PEF were recorded 30min after the completion of the
treatment. Increased PEF was the primary end point. Each subject was
evaluated and referred to hospital staff for further treatment, if necessary.
Subjects could have been withdrawn from the study at any time, if it
were determined by the study physician that the treatment was not
effective for any reason. Withdrawal criteria included, but were not limited
to, rapid decrease in oxygen saturation, respiratory distress and adverse
reaction to salbutamol including tremors or tachycardia. Subjects could
also withdraw from the study at their own discretion at any time. However,
no patients from either study group were withdrawn from the study for
any reason and no adverse events occurred.Figure 1. Human-powered nebuliser.
Assessed for eligibility (n=167)
Excluded  (n=57)
♦ Not meeting inclusion criteria
    (n=49)
♦ Declined to participate (n=8)
Randomized (n=110)
Allocated to intervention (n=55)
♦  Received allocated intervention (n=55)
Discontinued intervention (n=0)
Analysed (n=55)Analysed (n=55)
Discontinued intervention (n=0)
Allocated to intervention (n=55)
♦  Received allocated intervention (n=55)
Figure 2. Randomisation and analysis.
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Ethical approval
The trial was conducted in compliance with the Human Subjects
Institutional Review Boards of Marquette University, Milwaukee, WI, USA,
and the Universidad Salvadoreño Alberto Masferrer, San Salvador,
El Salvador. In addition, good clinical practices were followed.
Statistics
The primary objective of the study was to show that the HPN was not
different from EN in improving the primary outcome of improvement in
PEF. The primary end point was change in PEF, reported as absolute
change in PEF and change in percent-expected PEF after treatment.
Change in oxygen saturation was a secondary end point. The outcome
variables were compared by calculating 95% conﬁdence intervals (CIs) for
the differences between the means of the two treatment groups.
Equivalence was concluded if these ranges fell entirely within ± 20 l/min
for absolute change in PEF or ± 7% for change in percent-expected PEF.
This statistical analysis has been used in previously published equivalence
studies with PEF end points.13,14 With a two-sided alpha= 0.1, a s.d. of
30 l/min for PEF improvement and a tolerance limit of 20 l/min, 52 patients
were required in each group to achieve 95% power. All statistical analyses
were performed in R (version 2.15.1).15
RESULTS
A total of 110 patients, 39 males and 71 females, were recruited
for the study and were equally distributed between the HPN and
the EN groups. Ages ranged from 6 to 65 years; all assigned
participants received treatment and were included in the data
analysis. For each subject, temperature and blood pressure values
were all in the normal range and oxygen saturation levels were all
above 90%. Other clinical measurements are presented in Table 1.
Change in PEF and oxygen saturation after treatment along
with mean differences is reported in Table 2. No clinically
signiﬁcant differences between the HPN and EN groups were
found. The change in PEF for the HPN and EN groups ranged from
40 to 170 l/min and − 60 to 200 l/min, respectively. Mean
pretreatment oxygen saturation values for the HPN and EN
groups were 95.7% (95% CI, 95.0–96.4%) and 95.3% (95% CI,
94.7–95.9%) and post-treatment values were 97.1% (95% CI,
96.5–97.7%) and 97.1% (95% CI, 96.6–97.5%), respectively.
DISCUSSION
Main ﬁndings
To our knowledge, this study is the ﬁrst to compare the delivery of
a therapeutic agent by a manually operated nebuliser with a
commercially available jet nebuliser. This study demonstrates
clinical equivalence between the HPN and the DeVilbiss Pulmo-
Aide 5650D for the treatment of mild and moderate asthma.
Interpretation of ﬁndings in relation to previously published work
The equivalence between the compressors conﬁrms previous
ﬁndings in laboratory settings. The size of the particle droplets
generated by the HPN was shown to be equivalent to those
generated by the EN in another study under review. In addition, the
volume of liquid delivered per unit time was the same, as were
mean pressure and ﬂow from each unit. In the United States,
current FDA guidance indicates that laboratory testing alone is
sufﬁcient for the approval of new electric nebuliser compressor
medical devices. In the case of the HPN, however, clinical
veriﬁcation was considered to be an appropriate step as the
human power requirement introduces an additional variable.
Furthermore, this clinical study provides ‘in the ﬁeld’ proof of
function for Ministries of Health or non-governmental organisations
interested in implementing programmes involving such a device.
Strengths and limitations of this study
The Pulmo-Aide compressor was chosen because of its wide-
spread use and well-characterised performance, as documented
elsewhere.16 Certain nebuliser mouthpieces are susceptible to
performance differences when not positioned vertically. To limit
variability between patients, the Hudson Micro-Mist was chosen
because it performs consistently at a variety of angles and has also
been well studied.17,18 The fact that the HPN is equivalent to the
Pulmo-Aide compressor suggests that the HPN performs as well as
a popular and commonly used brand of nebuliser model. This
equivalence at this level of performance provides evidence for
Ministries of Health and global health organisations to recom-
mend the HPN for deployment studies and further testing in
regions where electricity is unreliable.
The study was limited to cases of mild and moderate asthma to
minimise risk to the subjects and to ensure that patients were in a
sufﬁciently stable condition and had ample time to decide whether
or not they wished to participate. After receiving the study dose of
salbutamol on either the HPN or the EN, participants were re-
evaluated by the attending physician in the respiratory therapy
area. Many participants received additional doses of salbutamol.
The decision was made to conduct post-treatment measurements
after a single dose for all participants to eliminate the complexity of
adjusting for varying numbers of doses between patients. Because
of these constraints, the increases in PEF and oxygen saturation
levels were modest, although signiﬁcantly increased.
There were a small number of subjects whose PEF or
oxygenation levels did not increase. For three subjects in the EN
group and two in the HPN group, PEF actually decreased slightly.
Table 1. Demographic and baseline patient data
Parameter HPN (n= 55) EN (n= 55)
Age, years (s.d.) 27 (20) 31 (22)
Female sex, n (%) 36 (65) 35 (64)
Height, cm (s.d.) 147 (23) 151 (22)
Weight, kg (s.d.) 55 (26) 58 (21)
Heart rate, beats/min (s.d.) 92 (18) 91 (15)
Respiratory rate, breaths/min (s.d.) 22 (4) 22 (4)
Abbreviations: EN, electric jet nebuliser compressor; HPN, human-powered
nebuliser.
Table 2. Outcome variables
HPN EN Mean difference P-value
Change in PEF, l/min 37.5 (26.7 to 48.2) 38.7 (26.1 to 51.3) 1.3 (−15.1 to 17.7) 0.877
Percent change in expected PEF 12.3 (9.1 to 15.5) 13.8 (9.8 to 17.9) 1.5 (−3.6 to 6.6) 0.552
Percent change in PEF 16.0 (11.1 to 20.9) 19.2 (12.3 to 26.2) 3.2 (−5.2 to 11.6) 0.451
Percent change in oxygen saturation 1.5 (0.8 to 2.1) 1.8 (1.2 to 2.4) 0.3 (− 0.6 to 1.2) 0.496
Values are mean (95% CI).
Abbreviations: EN, electric jet nebuliser compressor; HPN, human-powered nebuliser; PEF, peak expiratory ﬂow.
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The small number of non-responders in each group may have
required an additional dose of salbutamol or had an undiagnosed
lung pathology. Oxygen saturation improved modestly but
signiﬁcantly. The small level of increase is consistent with the
study design of mild-to-moderate asthma symptoms. On the basis
of this study and the laboratory evidence, the authors are
conﬁdent that the HPN would perform equivalently to an electric
nebuliser in the treatment of more severe asthma symptoms.
Implications for future research, policy and practice
Respiratory therapy is a leading cause of clinic utilisation in El
Salvador. In rural areas, patients frequently travel long distances to
the nearest Ministry of Health clinic to receive nebulised treatment
and often return on subsequent days for additional therapy,
incurring both travel costs and lost productivity. Requiring patients
to travel while having difﬁculty breathing could further exacerbate
their symptoms, thus prolonging their recovery and increasing the
number of treatments they require. With the HPN, community
health workers could be trained to deliver community-based
respiratory care. After the initial diagnosis by a physician in a health
centre, prescribed therapies would then be delivered by the
community health worker at a location near the patient’s home.
Community health workers would monitor the patient and make
referrals for additional treatment if necessary. This could at once
reduce health centre burdens, improve the quality of care for the
patient and reduce health system cost. Future research will explore
the feasibility and cost of implementing such a programme in rural
areas without access to electricity. In addition, the design of the
HPN is open-source, and the plan for HPN deployment is to
minimise cost to the users via not-for-proﬁt mechanisms.
CONCLUSIONS
The human-powered nebuliser compressor is equivalent to a
standard nebuliser compressor for the treatment of mild-to-
moderate asthma. Given the global prevalence of respiratory
diseases that require a nebuliser for effective diagnosis and
treatment, the implementation of a low-cost nebuliser compressor
that does not require electricity could signiﬁcantly reduce the
social and economic burden that these diseases impose on
patients and communities worldwide.
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